Age‐related influences on the clinical characteristics of new‐onset hallucinations in Parkinson's disease patients
Identifieur interne : 003601 ( Main/Exploration ); précédent : 003600; suivant : 003602Age‐related influences on the clinical characteristics of new‐onset hallucinations in Parkinson's disease patients
Auteurs : Christopher G. Goetz [États-Unis] ; Joanne Wuu [États-Unis] ; Linda Curgian [États-Unis] ; Sue Leurgans [États-Unis]Source :
- Movement Disorders [ 0885-3185 ] ; 2006-02.
Descripteurs français
- Pascal (Inist)
- Wicri :
- topic : Homme.
English descriptors
- KwdEn :
- Age Factors, Aged, Antiparkinson Agents (adverse effects), Antiparkinson Agents (therapeutic use), Cerebral Cortex (physiopathology), Drug Therapy, Combination, Female, Hallucination, Hallucinations (chemically induced), Hallucinations (diagnosis), Hallucinations (physiopathology), Human, Humans, Interview, Psychological, Levodopa (adverse effects), Levodopa (therapeutic use), Longitudinal Studies, Male, Mental Status Schedule, Middle Aged, Nervous system diseases, Parkinson Disease (diagnosis), Parkinson Disease (drug therapy), Parkinson Disease (physiopathology), Parkinson disease, Parkinson's disease, Risk Factors, Senescence, Treatment, aging, dopaminergic therapy, hallucinations.
- MESH :
- chemical , adverse effects : Antiparkinson Agents, Levodopa.
- chemical , therapeutic use : Antiparkinson Agents, Levodopa.
- chemically induced : Hallucinations.
- diagnosis : Hallucinations, Parkinson Disease.
- drug therapy : Parkinson Disease.
- physiopathology : Cerebral Cortex, Hallucinations, Parkinson Disease.
- Age Factors, Aged, Drug Therapy, Combination, Female, Humans, Interview, Psychological, Longitudinal Studies, Male, Mental Status Schedule, Middle Aged, Risk Factors.
Abstract
The objective of this study was to determine the demographic influences on the sensory characteristics (pure visual vs. nonvisual or mixed visual/nonvisual) of new‐onset hallucinations in Parkinson's disease (PD). We utilized 6‐year longitudinal interview data from 60 PD patients who had never hallucinated at baseline and reinterviewed them at 6, 18, 48, and 72 months to assess the presence and type of hallucination that developed as the first form of hallucination. We analyzed data by Generalized Estimating Equations methods and by nonparametric tests. Over 6 years, 37 of 60 patients developed hallucinations, and the first hallucinations were pure visual in 18, pure nonvisual in 9, and mixed visual/nonvisual in 10. At the time of first onset of hallucinations, patients whose hallucinations were nonvisual or mixed were significantly older than those with purely visual hallucinations (mean age, 69.8 ± 8.3 vs. 61.9 ± 10.6; P = 0.031). PD duration in the two groups, however, was statistically comparable (9.6 ± 4.4 vs. 12.9 ± 8.6 years). Though classically described as visual, hallucinations in PD frequently involve other sensory modalities. Age‐related disinhibition may facilitate wider cortical activation in PD and potentiate aberrant signaling that invokes other types of hallucinations besides the classic visual forms. © 2005 Movement Disorder Society
Url:
DOI: 10.1002/mds.20701
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 002916
- to stream Istex, to step Curation: 002916
- to stream Istex, to step Checkpoint: 002062
- to stream PubMed, to step Corpus: 002E73
- to stream PubMed, to step Curation: 002E73
- to stream PubMed, to step Checkpoint: 002E90
- to stream Ncbi, to step Merge: 001439
- to stream Ncbi, to step Curation: 001439
- to stream Ncbi, to step Checkpoint: 001439
- to stream Main, to step Merge: 004916
- to stream PascalFrancis, to step Corpus: 001C47
- to stream PascalFrancis, to step Curation: 001074
- to stream PascalFrancis, to step Checkpoint: 001C45
- to stream Main, to step Merge: 004D40
- to stream Main, to step Curation: 003601
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Age‐related influences on the clinical characteristics of new‐onset hallucinations in Parkinson's disease patients</title>
<author><name sortKey="Goetz, Christopher G" sort="Goetz, Christopher G" uniqKey="Goetz C" first="Christopher G." last="Goetz">Christopher G. Goetz</name>
</author>
<author><name sortKey="Wuu, Joanne" sort="Wuu, Joanne" uniqKey="Wuu J" first="Joanne" last="Wuu">Joanne Wuu</name>
</author>
<author><name sortKey="Curgian, Linda" sort="Curgian, Linda" uniqKey="Curgian L" first="Linda" last="Curgian">Linda Curgian</name>
</author>
<author><name sortKey="Leurgans, Sue" sort="Leurgans, Sue" uniqKey="Leurgans S" first="Sue" last="Leurgans">Sue Leurgans</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:0299D50B2C12512DA63614A58905BFA17478BA35</idno>
<date when="2006" year="2006">2006</date>
<idno type="doi">10.1002/mds.20701</idno>
<idno type="url">https://api.istex.fr/document/0299D50B2C12512DA63614A58905BFA17478BA35/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">002916</idno>
<idno type="wicri:Area/Istex/Curation">002916</idno>
<idno type="wicri:Area/Istex/Checkpoint">002062</idno>
<idno type="wicri:doubleKey">0885-3185:2006:Goetz C:age:related:influences</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:16161144</idno>
<idno type="wicri:Area/PubMed/Corpus">002E73</idno>
<idno type="wicri:Area/PubMed/Curation">002E73</idno>
<idno type="wicri:Area/PubMed/Checkpoint">002E90</idno>
<idno type="wicri:Area/Ncbi/Merge">001439</idno>
<idno type="wicri:Area/Ncbi/Curation">001439</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">001439</idno>
<idno type="wicri:doubleKey">0885-3185:2006:Goetz C:age:related:influences</idno>
<idno type="wicri:Area/Main/Merge">004916</idno>
<idno type="wicri:source">INIST</idno>
<idno type="RBID">Pascal:06-0171958</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">001C47</idno>
<idno type="wicri:Area/PascalFrancis/Curation">001074</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">001C45</idno>
<idno type="wicri:doubleKey">0885-3185:2006:Goetz C:age:related:influences</idno>
<idno type="wicri:Area/Main/Merge">004D40</idno>
<idno type="wicri:Area/Main/Curation">003601</idno>
<idno type="wicri:Area/Main/Exploration">003601</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Age‐related influences on the clinical characteristics of new‐onset hallucinations in Parkinson's disease patients</title>
<author><name sortKey="Goetz, Christopher G" sort="Goetz, Christopher G" uniqKey="Goetz C" first="Christopher G." last="Goetz">Christopher G. Goetz</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois</wicri:regionArea>
<placeName><region type="state">Illinois</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Wuu, Joanne" sort="Wuu, Joanne" uniqKey="Wuu J" first="Joanne" last="Wuu">Joanne Wuu</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois</wicri:regionArea>
<placeName><region type="state">Illinois</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Curgian, Linda" sort="Curgian, Linda" uniqKey="Curgian L" first="Linda" last="Curgian">Linda Curgian</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois</wicri:regionArea>
<placeName><region type="state">Illinois</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Leurgans, Sue" sort="Leurgans, Sue" uniqKey="Leurgans S" first="Sue" last="Leurgans">Sue Leurgans</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois</wicri:regionArea>
<placeName><region type="state">Illinois</region>
</placeName>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="2006-02">2006-02</date>
<biblScope unit="vol">21</biblScope>
<biblScope unit="issue">2</biblScope>
<biblScope unit="page" from="267">267</biblScope>
<biblScope unit="page" to="270">270</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">0299D50B2C12512DA63614A58905BFA17478BA35</idno>
<idno type="DOI">10.1002/mds.20701</idno>
<idno type="ArticleID">MDS20701</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Age Factors</term>
<term>Aged</term>
<term>Antiparkinson Agents (adverse effects)</term>
<term>Antiparkinson Agents (therapeutic use)</term>
<term>Cerebral Cortex (physiopathology)</term>
<term>Drug Therapy, Combination</term>
<term>Female</term>
<term>Hallucination</term>
<term>Hallucinations (chemically induced)</term>
<term>Hallucinations (diagnosis)</term>
<term>Hallucinations (physiopathology)</term>
<term>Human</term>
<term>Humans</term>
<term>Interview, Psychological</term>
<term>Levodopa (adverse effects)</term>
<term>Levodopa (therapeutic use)</term>
<term>Longitudinal Studies</term>
<term>Male</term>
<term>Mental Status Schedule</term>
<term>Middle Aged</term>
<term>Nervous system diseases</term>
<term>Parkinson Disease (diagnosis)</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Parkinson Disease (physiopathology)</term>
<term>Parkinson disease</term>
<term>Parkinson's disease</term>
<term>Risk Factors</term>
<term>Senescence</term>
<term>Treatment</term>
<term>aging</term>
<term>dopaminergic therapy</term>
<term>hallucinations</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Levodopa</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Levodopa</term>
</keywords>
<keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Hallucinations</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Hallucinations</term>
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Cerebral Cortex</term>
<term>Hallucinations</term>
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Age Factors</term>
<term>Aged</term>
<term>Drug Therapy, Combination</term>
<term>Female</term>
<term>Humans</term>
<term>Interview, Psychological</term>
<term>Longitudinal Studies</term>
<term>Male</term>
<term>Mental Status Schedule</term>
<term>Middle Aged</term>
<term>Risk Factors</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Hallucination</term>
<term>Homme</term>
<term>Parkinson maladie</term>
<term>Système nerveux pathologie</term>
<term>Sénescence</term>
<term>Traitement</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The objective of this study was to determine the demographic influences on the sensory characteristics (pure visual vs. nonvisual or mixed visual/nonvisual) of new‐onset hallucinations in Parkinson's disease (PD). We utilized 6‐year longitudinal interview data from 60 PD patients who had never hallucinated at baseline and reinterviewed them at 6, 18, 48, and 72 months to assess the presence and type of hallucination that developed as the first form of hallucination. We analyzed data by Generalized Estimating Equations methods and by nonparametric tests. Over 6 years, 37 of 60 patients developed hallucinations, and the first hallucinations were pure visual in 18, pure nonvisual in 9, and mixed visual/nonvisual in 10. At the time of first onset of hallucinations, patients whose hallucinations were nonvisual or mixed were significantly older than those with purely visual hallucinations (mean age, 69.8 ± 8.3 vs. 61.9 ± 10.6; P = 0.031). PD duration in the two groups, however, was statistically comparable (9.6 ± 4.4 vs. 12.9 ± 8.6 years). Though classically described as visual, hallucinations in PD frequently involve other sensory modalities. Age‐related disinhibition may facilitate wider cortical activation in PD and potentiate aberrant signaling that invokes other types of hallucinations besides the classic visual forms. © 2005 Movement Disorder Society</div>
</front>
</TEI>
<affiliations><list><country><li>États-Unis</li>
</country>
<region><li>Illinois</li>
</region>
</list>
<tree><country name="États-Unis"><region name="Illinois"><name sortKey="Goetz, Christopher G" sort="Goetz, Christopher G" uniqKey="Goetz C" first="Christopher G." last="Goetz">Christopher G. Goetz</name>
</region>
<name sortKey="Curgian, Linda" sort="Curgian, Linda" uniqKey="Curgian L" first="Linda" last="Curgian">Linda Curgian</name>
<name sortKey="Leurgans, Sue" sort="Leurgans, Sue" uniqKey="Leurgans S" first="Sue" last="Leurgans">Sue Leurgans</name>
<name sortKey="Wuu, Joanne" sort="Wuu, Joanne" uniqKey="Wuu J" first="Joanne" last="Wuu">Joanne Wuu</name>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003601 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003601 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Santé |area= MovDisordV3 |flux= Main |étape= Exploration |type= RBID |clé= ISTEX:0299D50B2C12512DA63614A58905BFA17478BA35 |texte= Age‐related influences on the clinical characteristics of new‐onset hallucinations in Parkinson's disease patients }}
This area was generated with Dilib version V0.6.23. |